- The methodologies to assess the effects of non-pharmaceutical interventions during COVID-19: a systematic review
- ³ Nicolas Banholzer^{1*‡}, Adrian Lison^{2*‡}, Dennis Özcelik³, Tanja Stadler², Stefan Feuerriegel^{1,4}, and
- 4 Werner Vach^{5,6}
- ¹ETH Zurich, Department of Management, Technology, and Economics, Zurich, Switzerland
- ⁶ ETH Zurich, Department of Biosystems Science and Engineering, Zurich, Switzerland
- ⁷ ETH Zurich, Chemistry | Biology | Pharmacy Information Center, Zurich, Switzerland
- ⁸ LMU Munich, LMU Munich School of Management, Munich, Germany
- ⁵Basel Academy for Quality and Research in Medicine, Basel, Switzerland
- ⁶University of Basel, Department of Environmental Sciences, Basel, Switzerland
- *Corresponding authors: nbanholzer@ethz.ch, adrian.lison@bsse.ethz.ch
- [‡]These authors contributed equally to this work.

$_{ ext{ iny Abstract}}$

- Non-pharmaceutical interventions, such as school closures and stay-at-home orders, have been implemented around the world to control the spread of SARS-CoV-2. Their effects on health-related outcomes have been the subject of numerous empirical studies. However, these studies show fairly large variation among methodologies in use, reflecting the absence of an established methodological framework. On the one hand, variation in methodologies may be desirable to assess the robustness of results; on the other hand, a lack of common standards can impede comparability among studies. To establish a comprehensive overview over the methodologies in use, we conducted a systematic review of studies assessing the effects of non-pharmaceutical interventions on health-related outcomes between January 1, 2020 and January 12, 2021 (n=248). We identified substantial variation in methodologies with respect to study setting, outcome, intervention, methodological approach, and effect assessment. On this basis, we point to shortcomings of existing studies and make recommendations for the design of future studies.
- 26 Keywords: non-pharmaceutical interventions, social distancing measures, control measures, COVID-
- 27 19, systematic review, methodology review

1 Introduction

In response to the COVID-19 pandemic, countries around the world have implemented nonpharmaceutical interventions. These include a variety of public health measures implemented
by governments with the intention of controlling, preventing, and mitigating transmission, e.g.
school closures, stay-at-home orders, and mandates for compulsory wearing of masks in public
places¹⁻⁴. The widespread use of these interventions has raised interest in empirically studying their
effects on health-related outcomes reflecting disease dynamics, e.g. the number of new cases or
infection rates⁵⁻¹⁰. Such studies can play an important role in informing the discussion about the
effectiveness of interventions. In particular, insights from the COVID-19 pandemic may contribute
to an evidence-based public-health response in subsequent COVID-19 waves or future pandemics.

Accordingly, a plethora of studies assessing the effects of non-pharmaceutical interventions during
the COVID-19 pandemic have been published. Their findings have been summarized by several

meta-analyses^{11–15}; nonetheless, each meta-analysis considered a different subset of studies. We
argue that the latter is due to substantial variation in the methodologies used to conduct empirical
studies on the effects of non-pharmaceutical interventions. The resulting lack of similarity constrains
meta-analyses to a comparably small and specific subset of the overall evidence.

There are different reasons to expect variation in methodologies in the studies on the effectiveness of non-pharmaceutical interventions for controlling a pandemic. One possibility is the lack of empirical data before the COVID-19 pandemic, so that early studies have been largely theoretical ¹⁶. Empirically assessing the effects of non-pharmaceutical interventions is therefore a relatively new subject, and corresponding studies do not build on an established scientific framework. Another possibility is that empirical assessments have been approached with different methods and domain knowledge by researchers from various fields, e.g. computational biology, infectious disease epidemiology, public health, economics, and statistical modeling.

Variation in methodologies can be manifold. Different study settings, outcomes, interventions, methodological approaches, and ways to assess effects may be used. On the one hand, such variation may be desired as it allows to assess the robustness of results against individual assumptions and methodologies. On the other hand, variation in methodologies can impede comparability among studies, which is necessary to arrive at conclusive evidence regarding the effects of non-pharmaceutical 7 interventions.

Here, we systematically review the methodologies for studying the effects of non-pharmaceutical interventions on health-related outcomes published between January 1, 2020 and January 12, 2021 (n=248). Thereby, we aim to inform about different methodologies that were used by previous studies and promote common standards so that future studies can align with existing ones. In particular, we explore shortcomings of current studies and provide seven recommendations for subsequent studies on the effects of non-pharmaceutical interventions.

2 Results

Our review follows general guidelines for systematic literature reviews¹⁷ and is reported according the PRISMA 2020 statement 18. The methodology was preregistered in a review protocol at PROS-PERO¹⁹. Figure 1 shows the PRISMA flow diagram of our identification process. We conducted a systematic database search for peer-reviewed research articles from January 1, 2020 up to January 12, 2021 (see Materials and methods, Section 5), yielding 2,929 unique records of studies for screening. Through title and abstract screening, we identified 411 studies as potentially relevant and evaluated their full texts. Of these, we excluded 163 studies that did not meet the eligibility criteria. The most frequent reasons for exclusion were that (i) studies primarily simulated the effects of interventions in hypothetical scenarios rather than making inferences from observational data; (ii) studies had a different objective than assessing intervention effects, and (iii) studies only assessed the effects of population behavior (most often mobility) on health-related outcomes, but not the effects of interventions. The remaining n=248 studies met our eligibility criteria and were included for subsequent data extraction. Importantly, 35 studies in our review sample contained multiple (i.e. up to three) analyses, e.g. with different methodological approaches, leading to 285 different analyses included. If not indicated otherwise, our results are presented at the level of individual analyses (and *not* at the level of studies). We characterized the analyses along five dimensions (SI Appendix D): study setting (D.1), 81 outcome (D.2), intervention (D.3), methodological approach (D.4), and effect assessment (D.5). In the Results section, if not stated otherwise, we use the term *interventions* to refer to nonpharmaceutical interventions. Where appropriate, we also point to exemplary studies of specific characteristics. Due to the large size of our review sample, however, we refrain from referencing

86 all studies in the main manuscript and instead refer to our complete data extraction report in SI

87 Appendix E.




Fig 1. PRISMA flow diagram. Overall, n=248 studies were included. Some studies contain multiple analyses, such that the number of analyses included in the review is 285.

2.1 Study setting

- The analyses vary in their scope across populations, geographic areas, and study period. A systematic
- classification of the study setting is shown in Table 1.

1 Population

- More than half of the analyses studied multiple populations (n=167; 59%), i.e. multiple countries
- 93 or subnational regions (e.g. states or cities). The remainder focused on a single population (n=118;
- 94 41%), i.e. a single country or subnational region. The analyses were performed at the national level
- 95 (n=117; 41%), the subnational level (n=97; 34%), or both (n=71; 25%). If both levels were studied,

Table 1. Systematic classification and frequency of the study setting (D.1).

D.1.1: Number of populations included	Frequency
Single (country, state, city, etc.)	118 (41 %)
Multiple (countries, states, cities, etc.)	167 (59%)
D.1.2: Level of populations included	
National (country-level)	117 (41 %)
Subnational (e.g. state-level)	$71\ (25\%)$
Both national and subnational (country- and e.g. state-level)	97 (34%)
D.1.3: Geographic areas covered ‡	
Asia	144 (51 %)
Europe	109 (38%)
North America	91 (32%)
Middle East and Africa	49~(17%)
Central and South America	$46 \ (16 \%)$
Oceania	$42\ (15\%)$
D.1.4: Number of countries covered	
Multiple countries	66 (23 %)
Single country (including multiple populations from a single country) [‡]	219 (77%)
↓ China	→ 54 (25 %)
→ United States	→ 43 (20%)
→ India	→ 11 (5 %)
	→ 11 (5 %)
→ Other	→ 100 (46%)
D.1.5: Study period	
Start and end date span first epidemic wave	161 (56%)
One or more exceptions [‡]	124~(44%)
→ End date in growth phase of wave	→ 44 (35 %)
\hookrightarrow Same end date for several populations with diverse epidemic trajectories	→ 38 (31 %)
→ End date at peak of wave	→ 16 (13%)
\hookrightarrow End date could not be evaluated	→ 14 (11 %)
\hookrightarrow Other	→ 14 (11 %)

 $[\]ddagger$ Multiple categories per analysis are possible. Frequencies refer to number of analyses to which category applies, proportions thus do not sum to $100\,\%.$

the country and all its subnational regions were oftentimes considered, e.g. all states of the United States. Geographically, Asia (n=144; 51%), Europe (n=109; 38%), and North America (n=91; 32%) were much more frequently analyzed than the rest of the world. Regional disparities may be explained by the fact that analyses frequently focused on some specific countries. For instance, in analyses of a single country, the most frequent country was China (n=54; 25%), from where the pandemic originated. Other frequently studied countries, such as the United States (n=43; 20%), India (n=11; 5%), and Italy (n=11; 5%), may have received more attention due to particularly high incidence and mortality during the first epidemic wave.

Study period

104

Typically, the study period covered both a rise and decline in new cases of the first epidemic wave 105 in the analyzed population, and started before and ended after the analyzed interventions were implemented (n=161; 56%). However, many analyses also deviated from this pattern in one or 107 several aspects. Most often, study periods had a comparatively early end date, i.e. the study period 108 ended already at the peak (n=16; 13%) or still in the growth phase (n=44; 35%) of the wave. There 109 was also a considerable number of analyses that used the same study period for populations which 110 were in different epidemic phases (n=38; 31%). In such cases, the end date of the study period was 111 still within the epidemic growth phase for some populations but already in the control phase for 112 other populations.

14 2.2 Outcome

The studies in our review sample used different types of health-related outcomes or surrogates. For every analysis, we identified the "raw outcome", i. e. the outcome data which were self-collected or obtained from external sources and used as input for the analysis. In around half of the analyses, the raw outcome was analyzed directly to assess the effects of interventions. The other half of analyses, however, involved an intermediate step, in which another outcome was computed from the raw outcome. This "computed outcome" was then analyzed instead of the raw outcome, or sometimes in addition to it. A systematic classification of the outcomes are shown in Table 2.

Raw outcome

We identified three main types of raw outcome data used, namely (i) epidemiological population-level data, (ii) epidemiological individual-level data, and (iii) behavioral data.

(i) Epidemiological population-level data

The majority of analyses used population-level data on epidemiological outcomes (n=223; 78%).

The most frequent types were surveillance data, mainly the number of confirmed cases, but also deaths, hospitalizations, recovered cases, and, less frequently, intensive care unit (ICU) admissions.

Importantly, some of these outcomes, such as recovered cases, were predominantly used to fit transmission models, in which case the effect of interventions was rather measured in terms of a different latent outcome (see D.5 Methodological approach, Section 2.4). Frequently, authors also

included several types of data (e. g. both cases and deaths), either to perform a separate analysis for
each (e. g. as a robustness check) or to combine them in a joint model (e. g. a transmission model).
Some analyses used surveillance data on other diseases than COVID-19, with influenza being the
most popular choice. Such surrogate diseases have often been monitored over an extended period of
time, which allows comparing their spread during the COVID-19 pandemic to earlier years. Notably,
we found only three analyses that used external data on latent epidemiological population-level
outcomes (e. g. the reproduction number). All other analyses using a latent outcome self-computed
it from raw data in an intermediate step (see D.2.2 Computed outcome, Section 2.2).

40 (ii) $Epidemiological\ individual$ -level data

Instead of population-level data, some analyses also used individual-level epidemiological data (n=23; 8%). These were in particular data about individual cases with case ID, demographics, and epidemiological characteristics (e.g. the date of symptom onset or travel history). In some instances, this included contact tracing data with links between index and secondary cases, allowing the reconstruction of transmission chains. Two analyses also used genome sequence data of clinical SARS-CoV-2 samples^{20,21}.

147 (iii) Behavioral data

In addition to epidemiological data, a relevant share of analyses employed data on population behavior (n=55; 19%), mainly mobility data. These data were usually obtained through tracking of mobile phone movements and provided as aggregates at the population level, based on summary statistics such as the daily number of trips made, distance travelled, time spent at certain locations, or population flow between regions. Another, less frequently used source of information on human behavior were surveys regarding social distancing practices, such as adherence to interventions, face mask usage, daily face-to-face contacts, or recent traveling.

Table 2. Systematic classification and frequency of the outcome (D.2).

D.2.1: Raw outcome [‡]	Frequency
Epidemiological population-level outcome [‡] ↓ Confirmed cases ↓ Deaths ↓ Recovered cases ↓ Hospitalizations ↓ Surrogate disease outcome ↓ Other Epidemiological individual-level outcome [‡] ↓ Individual cases ↓ Individual cases ↓ Genome sequence data Behavioral outcome [‡] ↓ Mobility ↓ Survey responses	223 (78%) L 186 (83%) L 64 (29%) L 20 (9%) L 18 (8%) L 10 (4%) L 24 (11%) 23 (8%) L 11 (48%) L 8 (35%) L 4 (17%) 55 (19%) L 50 (91%) L 6 (11%)
D.2.2: Time resolution of raw outcome	
Daily Other (weekly, biweekly, monthly, or not applicable)	269 (94 %) 16 (6 %)
D.2.3: Computed outcome [‡]	
None (only raw outcomes used) Measure of epidemic trend [‡] Growth rate Doubling time Other Epidemiological parameter [‡] Reproduction number Transmission rate Other Summary statistic Change points Other	$ \begin{array}{ccccccccccccccccccccccccccccccccccc$
D.2.4: Method to obtain the computed outcome	
None (no computed outcome) One or several methods used [‡] Ly Simple computation (e.g. ratio, sum etc.) Ly Exponential growth model Ly Compartmental transmission model Ly Statistical estimation of reproduction number Ly Other	$\begin{array}{c} 150 \ (53 \%) \\ 135 \ (47 \%) \\ $
D.2.5: Data source [‡]	
Could not be evaluated Data from (sub)national authorities Data from publicly available cross-country selections Mobility data from corporate organizations Other	10 (4 %) 141 (49 %) 77 (27 %) 40 (14 %) 54 (19 %)
D.2.6: Data availability	
Data access via source Data made available by the authors Data not accessible	173 (61 %) 76 (27 %) 36 (13 %)

 $[\]ddagger$ Multiple categories per analysis are possible. Frequencies refer to number of analyses to which category applies, proportions thus do not sum to 100 % .

Time resolution of raw data

Almost all raw data were obtained at daily resolution (n=269; 94%). Exceptions were data on surrogate diseases or from surveys, where reporting was usually only broken down in weekly, biweekly, or monthly intervals (n=16; 6%).

159 Computed outcome

155

Around half of the analyses involved an intermediate step, in which a latent outcome was computed from the raw data before assessing the effects of interventions. We identified four main types of computed outcomes:

- 1) Measures of epidemic trend (n=34; 12%) were computed to describe the overall trend of the epidemic, e.g. through the growth rate or doubling time of confirmed cases or hospitalizations.
- 2) Epidemiological parameters (n=89; 31%) were computed to measure specific infection dynamics, oftentimes in terms of the reproduction number. A few analyses also used individual-level epidemiological data to compute epidemiologically relevant time spans such as the serial interval or the time from symptom onset to isolation.
- 3) Summary statistics (n=8; 3%) were computed to describe the progression of an epidemic in a certain population, e.g. the time until a certain number of documented cumulative cases was reached, or the time until the reproduction number first fell below one.
- 172 4) Change points in the outcome (n=7; 2%) were computed with the aim to find time points of
 173 presumably structural changes in epidemic dynamics and compare them with implementation
 174 dates of interventions in the subsequent analysis 10, 22, 23. Typically, change points were computed
 175 for the time series of confirmed cases or mobility.

Of note, the raw outcome was not always used only for obtaining the computed outcome, e.g. changes both in the number of new confirmed cases (raw outcome) and in the reproduction number (computed outcome) were sometimes analyzed.

Method to obtain the computed outcome

179

180

181

1) Measures of epidemic trend were often obtained through simple computation (e.g. growth rate as percentage change in confirmed cases). Other analyses used simple modeling approaches,

- e.g. fitting an exponential growth model to the time series and extracting the exponential growth rate or doubling time from the estimated parameters.
- 2) Epidemiological parameters were mostly estimated from confirmed cases or deaths. Some 184 approaches fitted a compartmental transmission model to the raw epidemiological outcome. 185 For this, the parameter of interest was either allowed to vary over time, or the model was fitted 186 independently on different time periods. Other approaches employed a statistical method to 187 directly estimate reproduction numbers from the observed outcome. Here, the method by Cori 188 et al.²⁴ as implemented in the popular software package "EpiEstim"²⁵ for estimation of the 189 instantaneous effective reproduction number was used in a large number of analyses. However, 190 we found that statistical methods were not always applied correctly, which could have led to 191 bias in the inferred transmission dynamics (see SI Appendix A). Sometimes, authors also used 192 methods to estimate reproduction numbers from contact matrices²⁶ (derived from surveys on 193 personal contacts) or from transmission chains^{27,28} (derived from contact tracing data). 194
 - 3) Summary statistics were typically obtained through simple computation.
 - 4) Change points in the outcome were obtained by fitting a compartmental transmission model with special parameters representing points in time when the transmission rate changes. Other analyses used special change point detection algorithms.

Data source

182

183

195

196

197

198

199

The majority of authors directly accessed surveillance data from national health authorities or other 200 governmental bodies (n=141; 49%). In the case of individual-level data, which may be subject 201 to privacy regulations, authors were often themselves affiliated to the relevant health authority. 202 To obtain population-level data, a considerable share of analyses also used publicly available data 203 from cross-country selections (n=77; 27%), e.g. the European Centre for Disease Prevention and 204 Control (ECDC)²⁹, the Johns Hopkins University (JHU)³⁰, or Worldometer³¹, which offer aggregated surveillance data internationally from various sources for the pandemic. Mobile phone tracking 206 data were usually provided by corporate organizations (n=40; 14%) such as Google³², Apple³³, or 207 Baidu³⁴. A few analyses were also based on data collected by the authors, e.g. survey data on behavioral outcomes, seroprevalence studies, or data collected at a local facility such as a hospital.

Data availability

210

223

Data for the raw outcome was usually publicly available, in particular for epidemiological populationlevel outcomes such as cases and deaths because such data could oftentimes be accessed via the
source that is documented in the manuscript (n=173; 61%). In several cases, the data was made
publicly available by the study authors (n=76; 27%), e.g. by depositing the analyzed data in a
public repository. For a small, yet considerable number of analyses, data was not accessible (n=36;
13%) as the data was neither made publicly available nor the source of the data could be identified.
Of note, data on epidemiological individual-level data was typically not available due to privacy
concerns. Furthermore, corporate mobility data was widely available in the past, but access has
recently been restricted by many providers.

220 2.3 Intervention

The analyses vary in the types of exposures and non-pharmaceutical interventions. A systematic classification is shown in Table 3.

Terminology for non-pharmaceutical interventions

Varying terminology was used by the literature to refer to non-pharmaceutical interventions. This is 224 reflected in our search string, where we used a large set of terms in order to capture a broad range of 225 relevant studies. One part of our search string considers the different terminology for interventions 226 in general, while the other part considers the terminology for the specific type of non-pharmaceutical 227 interventions. In our review, the most frequent terms for interventions were "measures" (n=135; 228 54%), followed by "interventions" (n=65; 26%) and "policies" (n=16; 6%). The most frequent 229 terms for the specific type of non-pharmaceutical interventions were "non-pharmaceutical" (n=49; 230 16%), "control" (n=48; 16%), and "social distancing" (n=45; 15%). While terminology sometimes 231 reflected the specific types of non-pharmaceutical interventions that were analyzed, differences in 232 terminology may also be the result of different research backgrounds of the study authors. 233

Table 3. Systematic classification and frequency of the interventions (D.3).

D.3.1: Terminology for interventions †‡	Frequency
Not applicable (only specific term for intervention type) Measures Interventions Policies Other	22 (9 %) 135 (54 %) 65 (26 %) 16 (6 %) 14 (6 %)
D.3.2: Terminology for the specific type of non-pharmaceutical interventions †‡	Frequency
Not applicable (only general term for interventions) Non-pharmaceutical Control Social distancing Other	3 (1 %) 49 (16 %) 48 (16 %) 45 (15 %) 159 (52 %)
D.3.3: Exposure types	
One single intervention Multiple separate interventions One combination of interventions Multiple combinations of interventions All interventions together Other	43 (15 %) 31 (11 %) 84 (29 %) 20 (7 %) 70 (25 %) 37 (13 %)
D.3.4: Types of single interventions	
Not applicable (no single interventions analyzed) One or multiple single interventions analyzed (as defined in D.3.4 of the Documentation manual) Stay-at-home order Other School closure Workplace closure International travel restrictions Declaration of a state of emergency Bans of large gatherings Venue closure Bans of small gatherings	211 (74%) 74 (26%) 44 (59%) 27 (36%) 25 (34%) 20 (27%) 17 (23%) 13 (18%) 13 (18%) 14 12 (16%) 15 10 (14%)
D.3.5: Coding of interventions → D.3.6: Source of intervention data	
Not applicable (no specific interventions analyzed) Not necessary (no joint analysis of interventions across multiple populations) Could not be evaluated Government or news websites Other Necessary (joint analysis of interventions across multiple populations) Could not be evaluated Coding done by authors Use of externally coded data	74 (26%) $137 (48%)$ $498 (72%)$ $30 (22%)$ $49 (7%)$ $74 (26%)$ $49 (12%)$ $20 (27%)$ $45 (61%)$
D.3.7: Availability of data on exposure	
Not applicable (no specific interventions analyzed) Raw data documented in the manuscript Access to externally coded data via source Coded data made available by the authors Coded data not available	73 (26 %) 136 (48 %) 32 (11 %) 34 (12 %) 10 (4 %)

 $[\]dagger$ Results for this subdimension are reported at the study-level, and not the level of analysis (i.e. one study can contain multiple analyses). If a study uses more than one term predominantly, then both are counted and added to the total count.

 $[\]ddagger$ Multiple categories per analysis are possible. Frequencies refer to number of analyses to which category applies, proportions thus do not sum to $100\,\%$.

A considerable number of analyses examined one single $(n=43; 15\%)^{5,35}$ or multiple interventions

Exposure types and types of single interventions

234

235

separately (n=31; 11%)^{2,7}. Among these analyses, the effects of school closures (n=25; 34%) 236 and stay-at-home orders (n=44; 59%) were assessed most frequently, which may be due to these interventions being particularly controversial in the public discourse^{36,37}. The majority of analyses, 238 however, did not analyze the separate effects of multiple interventions but rather analyzed the joint 239 effect for a combination of multiple interventions $(n=84; 29\%)^{38-40}$, which is often the case when 240 multiple interventions were implemented on the same day and when thus the separate effects could not 241 be disentangled. A considerable number of analyses were even less specific by only analyzing whether 242 interventions were altogether effective but without attributing effects to specific interventions (n=70; 243 25%)^{41,42}. Other ways to assess the effectiveness of interventions were: examining the start time of 244 intervention^{23,43}, e.g. to assess the effect of different delays with which governments responded to 245 the pandemic⁴³; dividing the public health response into different periods^{44,45}; dividing interventions 246 into different categories 46,47; or summarizing the stringency of interventions to a numerical index at 247 a specific time point 48,49 . 248 Of note, analyses that assessed the effects of a combination of interventions often referred to this 249 combination as "lockdown". In the underlying analysis, such lockdowns typically included multiple interventions implemented on the same day^{39,50}. However, the specific interventions included in 251 lockdowns varied considerably between populations. We therefore considered "lockdown" as an 252 umbrella term for different combinations of interventions rather than as a specific type of intervention. Furthermore, some studies did not only assess the effects of non-pharmaceutical interventions on 254 mobility, but also the effects of changes in mobility on population-level epidemiological outcomes. 255 In these analyses, human mobility was typically defined as a continuous exposure. We extracted 256 information on such complementary analyses of mobility as an addendum to the main review (see SI 257 Appendix E). 258

Coding of interventions

259

When multiple populations were jointly analyzed, coding of interventions may have been necessary in order to reconcile differences in the definitions of interventions between populations. For instance, the term "school closures" could refer to the closure of primary or secondary schools or universities. Differences across populations are thus reconciled during coding by deciding upon the type of

intervention and providing a common name and definition that is then applied to all populations.

Such coding of interventions was necessary in around a quarter of analyses (n=74; 26%).

266 Source of intervention data

If coding of interventions was *not* necessary, authors often obtained intervention data (i. e. the date of interventions) from a government or news website (n=30; 22%). Unfortunately however, the data source was often not provided by the authors and could thus not be evaluated (n=98; 72%). If coding of interventions was necessary, then study authors either coded the data themselves (n=20; 27,%), i. e. collected the data from government or news websites and systematically categorized them, or used externally coded data instead (n=45; 61%). The most popular choices for externally coded data were the Oxford Government Response Tracker¹ and, for the United States, the New York Times⁵¹.

Availability of data on exposure

Authors using exposure data (type of exposure, interventions, and implementation dates) where
coding of interventions was not necessary usually documented the data in the manuscript. Some
authors using externally coded data chose to make the data available themselves (n=34; 12%), e. g.
by depositing it in a public repository, although many only referenced external data (n=32; 11%).

280 2.4 Methodological approach

A variety of methodological approaches were used to assess the effects of interventions. The methodological approaches extracted here describe the actual stage of estimating the intervention effect. A systematic classification of the methodological approaches is shown in Table 4.

Empirical approach

287

288

289

290

We distinguished three general empirical approaches for assessing the effects of interventions, namely (D) descriptive, (P) parametric, and (C) counterfactual approaches.

• (D) Descriptive approaches (n=151; 53%): These approaches provided descriptive summaries of the outcome over time or between populations, and related variation in these summaries to the presence or absence of different interventions. For example, some analyses compared changes in the growth rate of observed cases before and after interventions were implemented 52,53. Of

Table 4. Systematic classification and frequency of the methodological approach (D.4).

D.4.1: Empirical approach				Total freq.
D: Descriptive				151 (53%)
P: Parametric				94 (33 %)
C: Counterfactual				40 (14%)
D.4.2: Use of exposure variation	(D)	(P)	(C)	
Only variation over time for a single population	78	23	24	125 (44 %)
Only variation over time for multiple populations	63	22	10	95 (33%)
Only variation between populations	4	14	0	18 (6%)
Both variation over time and between populations	6	35	6	47~(16%)
D.4.3: Method				
Description of change over time	136	_		136 (48%)
→ Description of time course				→ 49 (36 %)
→ Comparison of time periods				→ 87 (64 %)
Comparison of populations	8	_		8 (3%)
Comparison of change points with intervention dates	7		_	7 (2%)
Non-mechanistic model	_	61	17	78 (27%)
→ Generalized linear model				→ 51 (65 %)
→ Exponential growth model				→ 11 (14 %)
→ Other				→ 16 (21 %)
Mechanistic model	_	30	13	43~(15%)
$\boldsymbol{\mathrel{\sc iiii}}$ Compartmental single-population transmission model				\rightarrow 29 (67 %)
$ \mathrel{\ \hookrightarrow \ }$ Compartmental meta-population transmission model				→ 4 (9 %)
→ Semi-mechanistic Bayesian transmission model				\rightarrow 5 (12%)
\hookrightarrow Other				\rightarrow 5 (12%)
Synthetic controls	_	_	6	6 (2%)
Other	0	3	4	7 (2%)
D.4.4: Code availability				
None (not available)	121	66	33	220~(77%)
Publicly available	30	28	7	65~(23%)

Empirical approach: (D) descriptive, (P) parametric, and (C) counterfactual

291

292

293

294

295

296

297

298

299

note, descriptive approaches could involve modeling as part of an intermediate step, where a latent outcome was computed from the raw outcome (see Computed outcome), while, afterward, a descriptive approach was used to assess the effect of interventions on the latent outcome. For example, some analyses used a single-population compartmental transmission model to estimate the time-varying reproduction number and then compared the reproduction number before and after interventions were implemented ^{54–56}.

• (P) Parametric approaches (n=94; 33%): These approaches formulated an explicit link between the intervention and the outcome, where the effects of interventions were quantified via a parameter in a model. Most frequently these were regression-like links to estimate the

 $[\]ddagger$ Multiple categories per analysis are possible. Frequencies refer to number of analyses to which category applies, proportions thus do not sum to $100\,\%$.

effects of interventions on the reproduction number^{2,8}.

• (C) Counterfactual approaches (n=40; 14%): These approaches assessed the effect of interventions by comparing the observed outcome with a counterfactual outcome based on an explicit scenario in which the interventions were not implemented. For example, the observed number of cases was compared with the number of cases that would have been observed if the exponential growth in cases had continued as before the implementation of interventions^{57,58}.

Use of exposure variation

300

301

302

303

304

305

Effects of interventions were assessed by exploiting variation in the exposure to the intervention 307 over time, between populations, or both. Assessments exploiting exposure variation over time 308 contrasted the outcome in time periods when specific measures were in place with the outcome in time periods when they were not in place. In contrast, assessments exploiting exposure variation 310 between populations were based on a comparison of the outcome between populations that were 311 subject to specific measures with populations that were not. In the majority of analyses, a single 312 population was studied and thus only variation over time could be exploited in order to assess the 313 effects of interventions (n=125; 44%). In around one third of analyses, multiple populations were 314 studied but only variation over time was exploited (n=95; 33%), i.e. the effects of interventions 315 were assessed within each population separately. A small number of analyses exploited only variation between populations (n=18; 6%). Less than one in five analyses exploited both variation over time 317 and between populations (n=47; 16%). 318

319 Method

323

We grouped the different methods used into (i) description of change over time, (ii) comparison of populations, (iii) comparison of change points with intervention dates, (iv) non-mechanistic model, (v) mechanistic model, and (vi) synthetic controls. We review these in the following.

(i) Description of change over time

The large majority of analyses following a descriptive approach examined the change of the outcome over time to assess the intervention effect (n=136; 48%). In some of these analyses, the focus was on the course of the outcome over time, typically by attributing the observed change (e.g. a reduction in new cases over time) to the analyzed interventions (n=49; 36%). For example, the outcome was

assessed at regular or irregular intervals, which were not necessarily aligned with the implementation dates of interventions 41,42,59 . The majority of analyses, however, followed the logic of an interrupted time series analysis, i. e. the outcome was explicitly compared between time periods before and after interventions (n=87; 64%) $^{60-63}$.

332 (ii) Comparison of populations

A few descriptive analyses compared outcomes via summary statistics only between populations
(i. e. without considering variation over time) to assess intervention effects (n=8; 3%). In such
analyses, the outcomes were compared between populations that were stratified by different exposure
to interventions (e. g. populations that implemented a certain intervention and populations that did
not)^{64–66}.

338 (iii) Comparison of change points with intervention dates

Some descriptive analyses checked whether the dates of estimated change points in outcomes and the implementation dates of interventions coincide $(n=7; 2\%)^{10,22,67}$. If both dates were more or less in agreement, this was taken as evidence confirming the effectiveness of the intervention. However, change point detection methods could also yield change points prior to the implementation of interventions, which was sometimes interpreted as a sign of additional factors influencing the outcome (e. g. proactive social distancing)²².

(iv) Non-mechanistic model

Non-mechanistic models are statistical models that typically make *no* explicit assumptions about the mechanisms that drive infection dynamics. Such models were used in both parametric and counterfactual approaches (n=78; 27%).

In parametric approaches, non-mechanistic models – almost always (generalized) linear regression models – were used to model a direct link between interventions and outcome. Typically, dummy variables were used to indicate when (variation over time)^{9,68,69} or where (variation between populations)^{70–72} interventions were implemented. Analyses exploiting both variation over time and between populations typically used panel regression methods^{5,73,74}.

In counterfactual approaches, the non-mechanistic models used were mostly exponential growth models, and sometimes time series models (e. g. AR(I)MA or exponential smoothing)^{38, 44, 58}. These

models were fitted using data prior to when an intervention was implemented and then extrapolated the outcome afterwards.

358 (v) Mechanistic model

384

Mechanistic models have a structure that makes, to some extent, explicit assumptions about the mechanisms that drive infection dynamics. They were used in both parametric and counterfactual approaches (n=43; 15%).

In parametric approaches, the effect of an intervention was represented via a parameter that
was functionally linked to the disease dynamics (i. e. via a latent variable) of the model. This was
typically achieved by parameterizing the transmission rate or reproduction number as a function of
binary variables, indicating whether interventions were implemented or not^{2,75–77}. Others linked the
effects of interventions to the contact rate, the transmission probability upon contact, or to entries
in the contact matrix^{78–80}. A few modeling approaches also represented the intervention via an
explicit structure or dynamic in the model, e. g. a compartment for quarantined individuals with a
quarantine rate^{47,81} or an exponential decay of the susceptible population^{46,47,82}.

The most popular mechanistic models used in parametric approaches were compartmental trans-370 mission models. These models were fitted to the time series of cases, hospitalizations, recovered cases, deaths, or several simultaneously. With the exception of one meta-population model⁸³, all 372 compartmental models used in analyses following a parametric approach were single-population 373 models. If multiple populations were analyzed, each population was modeled separately. A few 374 parametric analyses also used a semi-mechanistic Bayesian transmission model with a time-discrete 375 renewal process, similar to the one in an early influential paper by Flaxman et al.⁸. These analyses 376 fitted a Bayesian hierarchical model with stochastic elements for disease transmission and ascertainment on observed time series for cases, deaths, or both^{2,8,84}. The model was usually fitted to data 378 from several populations, modeling separately the time course in each population but estimating 379 the parameters for the intervention effects jointly across populations. Rarely, analyses used highly 380 complex models such as individual-based transmission models simulating the behavior of individual agents, or phylodynamic models inferring both virus phylogenies and transmission dynamics from 382 genome sequence data. 383

In counterfactual approaches, mechanistic models were, similar to non-mechanistic models,

calibrated to data before the implementation of an intervention and then projected the outcome for the time after the intervention, while keeping the model parameters fixed^{85–87}. Thus, no relationship between intervention and outcome is explicitly modeled. Regularly, these analyses used metapopulation or individual-based models that incorporated migration dynamics through mobility data and a network between individuals or populations^{87–89}.

390 (vi) Synthetic controls

Some counterfactual approaches used synthetic control methods (n=6; 2%). Here, a counterfactual scenario was constructed by computing the counterfactual outcome as a weighted combination of observations from a pool of "control" populations in which the intervention was not implemented ^{43, 90, 91}. Weights were fitted so as to give more importance to control populations similar to the intervention population. In these analyses, the course of the outcome before intervention was often used as the primary measure of similarity ^{6, 90, 91}. Sometimes, further factors such as geographic proximity or population characteristics were also considered ^{90, 92}.

398 Code availability

For around one in four analyses, a link to a publicly accessible repository containing the computer code implemented for a specific analysis was provided (n=65; 23%). Overall, the code availability was comparably higher for parametric approaches, where one in three analyses provided a link.

402 2.5 Effect assessment

The analyses in our review sample varied in their form of effect assessment, i.e. how the effect was quantified, whether uncertainty was reported, and whether sensitivity analyses or subgroup assessments were conducted. A systematic classification of the effect assessment is shown in Table 5.

406 Reporting of intervention effect, measure of effect, and reporting of uncertainty

The are difference in how effects of interventions were reported. Around one in five analyses made
a qualitative assessment of the intervention effect (n=53; 19%), e.g. by qualitatively describing
the change in the outcome over time following the implementation of interventions. More frequent
was the reporting of comparisons of outcome values to assess the intervention effect (n=73; 26%),
i.e. by comparing the outcome values before an intervention with the outcome values after an
intervention. Around half of the analyses reported a quantitative change in outcome values (n=159;

Table 5. Systematic classification and frequency of different effect assessments (D.5).

D.5.1: Reporting of intervention effect				Total freq.
QS: Qualitative statement				53 (19%)
CO: Comparison of outcome values				73~(26%)
QC: Quantification of change in outcome values				159 (56%)
D.5.2: Measure of effect ‡	(QS)	(CO)	(QC)	
Change in reproduction number	22	44	29	95 (33%)
Change in confirmed cases	16	15	38	69(24%)
Change in mobility	9	6	28	$43\ (15\%)$
Other	18	29	100	147 (52%)
D.5.3: Reporting of uncertainty				
Not applicable				52 (18%)
Yes				154 (54 %)
No				79(28%)
D.5.4: Sensitivity analysis (including compute	ed outcomes)			
None (no sensitivity analyses w.r.t effect)				217 (76 %)
One ore more sensitivity analyses one or more sensitivity analyses [‡]			68 (24%)	
→ Model specification varied				→ 36 (53 %)
→ Epidemiological parameters varied				→ 29 (43 %)
→ Different or modified outcome used				→ 17 (25 %)
→ Same analysis with (sub)population excluded				\rightarrow 16 (24 %)
\hookrightarrow Different coding of interventions used				→ 10 (15 %)
\hookrightarrow Start or end date of study period varied				→ 4 (6%)
D.5.5: Subgroup assessment				
None (no subgroups)				250 (88 %)
One or more subgroups [‡]				35 (12%)
→ Based on socioeconomic indicators				→ 23 (66 %)
→ Based on epidemiological indicators				→ 16 (46 %)
→ Based on public health response				→ 9 (26 %)
→ Based on geographic areas				→ 6 (17%)

Reporting of intervention effect: (QS) qualitative statement, (CO) comparison of outcome values, and (QC) quantification of change in outcome values

or estimating the difference via a parameter in a statistical model. The intervention effect was oftentimes measured in terms of a change in the reproduction number (n=95; 33%), in confirmed cases (n=69; 24%), or in mobility (n=43; 15%), but many other measures of effect were also common. Notably, a relevant number of analyses in our review sample focused its methodology on estimating the reproduction number as the computed outcome and then conducted only a qualitative assessment of the intervention effects afterwards. Uncertainty was reported in around one half of the analyses (n=154; 54%), e.g. via standard error, confidence intervals, and credible intervals.

 $[\]ddagger$ Multiple categories per analysis are possible. Frequencies refer to number of analyses to which category applies, proportions thus do not sum to $100\,\%$.

Sensitivity analyses

421

We checked all works for sensitivity analyses that were specifically conducted to examine the robustness of the reported intervention effects. Many studies conducted sensitivity analyses only related to the predicted outcome or model fit, but not to the intervention effect. Overall, the vast majority of analyses did not conduct sensitivity analyses with regard to the intervention effect (n=217; 76%).

Of those that did, sensitivity analyses focused on model extensions or adjustments in which the 427 model specification was varied (n=36; 53%), e.g. by changing the structure of a transmission model 428 or by adjusting the estimated effects of interventions for additional variables in a regression model. 429 Others analyzed sensitivity with respect to variations in epidemiological parameters (n=29; 43%), 430 e.g. by assuming a different basic reproduction number, generation or serial interval, infectious 431 period, or reporting delay distribution. Only few analyses tested sensitivity with regard to data: i.e. 432 using different or modified outcomes^{69,93} (n=17; 25%); using a different coding of interventions^{3,7} 433 (n=10; 15%); or repeating the same analysis but excluding (sub)populations² (n=16; 24%). Of the 434 different methodological approaches, analyses with semi-mechanistic Bayesian transmission models 435 generally conducted more comprehensive sensitivity analyses. For example, one work² performed 436 checks regarding data, model, and epidemiological parameters and presented the results prominently in the main manuscript. 438

439 Subgroup assessment

The effects of interventions were rarely assessed within subgroups of the population (n=35; 12%).

Two thirds of such assessments were within subgroups created based on socioeconomic indicators (n=23; 66%), e.g. assessing intervention effects within groups of individuals of different age and gender or assessing the effect of lockdown within low- and high-income income regions Less frequent were subgroups based on epidemiological indicators, the public health response frequent were subgroups based on epidemiological indicators, the public health response geographic areas.

446 3 Discussion

Our systematic review covers over 240 studies published between January 2020 and January 2021.

48 Insights from this review can inform different types of future studies: (i) studies using data from

the same period that extend our knowledge on aspects that have so far been rarely investigated;

(ii) studies using data from subsequent periods that generate new insights or corroborate existing

ones; and (iii) studies using data from a future pandemic caused by another virus. Although the

preconditions to conduct these studies differ, they share the goals and challenges of the studies in

our review sample. Accordingly, the results from our systematic review allow us to make seven

recommendations for the design of future studies, which are discussed in the following.

Recommendation 1: Exploring the value of rarely analyzed outcomes

455

During the COVID-19 pandemic, both surveillance data on confirmed cases, hospitalizations, or deaths^{29,30}, and mobility data from mobile phones^{32,33} have become publicly available at scale. This has enabled a large number of studies assessing the effect of non-pharmaceutical interventions on population-level epidemiological outcomes and on human mobility (Table 2, D.2.1). However, there remains considerable potential to explore the value of other outcomes and data sources that have so far been rarely analyzed.

First, more detailed insights into the effects of non-pharmaceutical interventions could be gained 462 from using individual-level data. This has been demonstrated by studies in our review sample, e.g. 463 by relating the effects of non-pharmaceutical interventions to the serial interval using symptom onset 464 data⁴¹, to transmission chains using contact tracing data⁸⁷, or to virus migration rates using genome 465 sequence data²⁰. We hope to see more such analyses as more individual-level data becomes available. Second, there can be great merit in analyses advancing our understanding of the mechanisms by 467 which non-pharmaceutical interventions work. Our review sample contained many analyses assessing 468 the effects of interventions on human behavior, or of human behavior on epidemiological outcomes. 469 The majority of these analyses used mobility data from mobile phones (Table 2, D.2.1); however, more 470 effort is needed to obtain a complete picture of how population behavior mediates the effects of non-471 pharmaceutical interventions. For example, interventions may influence behaviour and transmission through further factors not captured by previous studies, and, moreover, the relationship between mobility and disease transmission may change over time^{96,97}. Additional insights can be gained from 474 analyses using behavioral data from other sources, e.g. surveys evaluating compliance with mask 475 mandates⁶² or the number of daily contacts⁹⁸. Moreover, we see value in analyzing interventions, behavior and epidemiological outcomes jointly, i. e. in the form of a mediation analysis ^{99,100}, allowing

to differentiate the direct and indirect effect of non-pharmaceutical interventions.

479 Recommendation 2: Exploiting variation in the exposure to interventions between populations

Variation in the exposure to interventions (i.e. when, where and which interventions were imple-480 mented) is required in order to empirically assess their effects. Variation over time was the most 481 common choice in our review sample (Table 4, D.4.2). Here, the effects were previously assessed within populations based on differences in outcomes before and after non-pharmaceutical interven-483 tions were implemented. However, such changes may falsely be attributed to non-pharmaceutical 484 interventions if they are subject to confounding by concurring time trends. We thus recommend to also exploit exposure variation between populations, i.e. with respect to the timing and the types of 486 single interventions that were implemented. This was done by only one in five analyses in our review 487 sample (Table 4, D.4.2), although the types and timing of interventions varied considerably between the populations. This leaves a valuable source of variation largely untapped. 489

Recommendation 3: Dissecting the effects of single interventions

Evidenced-based decision making requires empirical estimates for the effects of single nonpharmaceutical interventions (e. g. school closures or stay-at-home orders). However, the majority of
analyses assessed the effects of population-specific combinations of interventions such as lockdowns
(Table 3, D.3.3). The underlying analyses typically studied only a single population (or multiple
populations separately) where multiple interventions were implemented on the same day, and, as a
result, the separate effects of interventions cannot be disentangled. For future work, we recommend
more effort to conduct analyses across multiple populations, so that the separate effects of single
interventions can be dissected.

499 Recommendation 4: Careful coding of interventions

Systematic coding of intervention data is necessary to compare the effects of non-pharmaceutical interventions across multiple populations (Tabble 3, D.3.5). However, the process of such systematic coding involves subjective decisions regarding if and when non-pharmaceutical interventions have been implemented². These decisions are sometimes unavoidable, and they are also inherent to the development of public databases¹⁰¹. As a result, different coding of interventions could impact the results, and, therefore, coding decisions should be made transparent and documented carefully.

In addition, we recommend to examine empirically the impact when using a different coding of

interventions, e.g. by comparing the results across different input data.

Recommendation 5: Promoting comparability across different analyses

508

During a pandemic, public health policy has a strong focus on the number of confirmed cases, hospi-509 talizations, and deaths, making them obvious outcomes to evaluate the effectiveness of interventions. 510 However, non-pharmaceutical interventions act only indirectly or with a certain delay on these observable outcomes. Typically, non-pharmaceutical interventions should influence the behaviour 512 of the population, which should reduce transmission (e.g. by limiting the contact rate), which in 513 turn should affect the number of new infections and, subsequently, observed outcomes like confirmed cases, hospitalizations, or deaths. The question of how to assess intervention effects along this path 515 has been answered differently by the studies in our review sample. We identified four main types of 516 analyses; see (1)-(4) in Box 1. In the following, we discuss the different types with regard to their 517 ability of enabling a comparison of results between studies.

Box 1. Different types of analyses to assess the effects of non-pharmaceutical interventions.

(1) Observed outcome directly linked to interventions

A raw, observed outcome is analyzed directly by evaluating differences (i) over time with an interrupted time-series analysis comparing the outcome before vs. after an intervention, (ii) between populations with a cross-sectional analysis comparing populations exposed vs. not exposed to an intervention, or (iii) both over time and between populations with a panel data analysis. Mechanistic modeling is typically not involved in this type of analysis, with one exception, namely counterfactual approaches using a transmission model to project the observed outcome after intervention.

(2) Computed, unobserved outcome linked to interventions

In contrast to type (1), the intervention effect is measured in terms of an unobserved outcome. This is computed from the raw outcome and then analyzed in a similar manner as in (1). Mechanistic modeling can be involved in computing the unobserved outcome, for example by using a model to estimate the reproduction number or transmission rate from the number of new cases.

(3) Observed outcome linked to interventions via unobserved outcome in mechanistic model

Observed outcomes are used to fit a mechanistic model (e. g. compartmental transmission model) that includes a latent variable representing an unobserved outcome (e. g. the reproduction number), which in turn is parameterized as a function of interventions. For instance, a regression-like link is used within the mechanistic model to estimate the effect of interventions on the transmission rate as a latent variable.

(4) Change points in outcome related to exposure

Change points are estimated in the time series of an observed or unobserved outcome. The estimated change points are then related to the implementation dates of interventions. If the estimated change points agree well with the actual implementation dates of interventions, this is interpreted as evidence for the effectiveness of interventions.

Analyses of type (1), where the observed outcome is directly linked to interventions, can avoid

520

539

540

541

mechanistic modeling by directly analyzing an observed outcome such as cases or deaths. Here, a 521 central challenge is to take into account the uncertain delay between the implementation of non-522 pharmaceutical interventions and their effects on the observable outcome. The fact that infections 523 and subsequent outcomes such as confirmed cases follow exponential dynamics during an epidemic 524 wave makes it difficult to compare intervention effects measured by observable outcomes across different epidemic phases. In contrast to that, analyses following type (2) or (3) employ mechanistic modeling, allowing to assess the effects of interventions on latent, unobservable outcomes such as 527 the transmission rate or the reproduction number. Since these latent outcomes can be inferred from 528 different observed outcomes like cases or deaths, it becomes possible to compare analyses that use different raw data. The difference between type (2) and (3) is that for (2) the estimation of the latent 530 outcome is separated from the effect assessment. Such separation reduces model complexity, however, 531 often at the expense of incomplete uncertainty assessments. The reason is that most analyses based 532 on type (2) only incorporated uncertainty involved in modeling the effect of interventions on the 533 latent outcome, thus leaving out uncertainty involved in the computation of the latent outcome. 534 This also means that differences in uncertainty assessments must be carefully taken into account 535 when synthesizing results from multiple studies. 536 Finally, analyses following type (4), where change points in the outcome are related to the 537 538

exposure, take a very different approach that shares few assumptions with the other approaches. A comparison of change points can verify the presence of an effect, yet without quantifying its size. As a result, such findings are best complemented with an analysis of type (1), (2), or (3).

Recommendation 6: Understanding variation in effectiveness across subgroups

The effects of non-pharmaceutical interventions may vary between and within populations. However, only one in ten analyses in our review sample examined variation across subgroups or populations (Table 4, D.4.2). Estimating and explaining such variation could help understand the conditions under which interventions are more or less effective for a specific subgroup, potentially allowing policy makers to tailor interventions to a specific subgroup or setting. Our review points out two approaches that can contribute towards a better understanding of the varying effectiveness of non-pharmaceutical interventions: (i) comparing the effects of interventions between subgroups of the same population (e.g. between the young and elderly population); and (ii) comparing the effects of interventions between different populations and relating differences to population-specific characteristics (e.g. population density).

Recommendation 7: Assessing sensitivity within and between studies

While variation in methodologies can complicate the comparability among studies, it may help to identify the influence of certain methodological choices on the results. Here, the public availability of 554 data for outcomes and interventions holds potential for sensitivity analyses within studies as well as 555 comparisons between studies. Specifically, the same analysis could be repeated with different sets of publicly available data as part of the same study. This way, sensitivity of the findings with respect to 557 the choice of outcome and intervention data could be assessed within studies, reducing the risk of bias 558 from specific outcome data (e.g., incomplete case ascertainment due to limited testing capacity etc.) 559 or the specific coding of interventions. For example, the number of new cases, deaths, or both could 560 be used as the raw outcome in mechanistic models with a comparable latent outcome². However, 561 other aspects, in particular the specific setting and methodologies used, are presumably more difficult 562 to vary as part of a sensitivity analysis, and may therefore need to be compared between different 563 studies. Important for such comparisons is giving access to the preprocessed data, yet most study 564 authors accessed these data directly from national authorities or external data providers without 565 making the preprocessed data additionally available (Table 2, D.2.5-D.2.6 and Table 3, D.3.6-D.3.7). To promote reproducibility, study authors should always make the preprocessed data available for 567 two reasons. First, future access to the data via the original source may be restricted (this has 568 already been observed for corporate mobility data). Second, originally analyzed and recently accessed data may be different as publicly available epidemiological data and coded intervention data can be 570 subject to updates, revisions, and corrections. In addition, publication of computed code is crucial 571 to support comparisons of methodological approaches, specific modeling choices, and input data.

4 Conclusions

552

Our review of more than 240 studies on the effects of non-pharmaceutical interventions revealed substantial variation in methodologies. Until specific best practices emerge, further heterogeneity in studies is inevitable and can also be beneficial, e.g. for assessing robustness of the results with respect to method and input data. Nevertheless, some standardization is required in order to synthesize evidence on the effects of non-pharmaceutical interventions from multiple studies. So far, a lack of common standards and substantial variation in the methodologies used have created a challenge for meta-analyses to summarize and compare the reported effects from existing studies^{11–15}. Here, our methodology review can serve as a basis for subsequent meta-analyses to factor in the variety of existing methodologies when pooling and comparing the large number of effects that have been reported for non-pharmaceutical interventions on health-related outcomes. More importantly though, our review promotes common standards and reduces barriers to comparability across studies by making recommendations for the design of future studies.

A general limitation of the studies included in our review is that it is difficult to estimate causal effects based on population-level observational data and to rule out unobserved confounding. This is also highlighted by the persistent debate on the role of voluntary behavioral change in curbing transmission^{102–105}. Evidence from observational studies on the effects of non-pharmaceutical interventions should thus be evaluated in conjunction with evidence from other fields. For example, evidence on the infectiousness of school children and parental strategies to fill the care gap can produce independent predictions about the effects of school closures. Similarly, laboratory evidence regarding the effectiveness of masks together with evidence on compliance with masks can produce independent predictions of the effectiveness of mask mandates.

During the COVID-19 pandemic, a tremendous amount of publicly available epidemiological data has been generated. The ease of access to this data allowed many researchers to contribute work, using a variety of methodologies to assess the effects of non-pharmaceutical interventions on health-related outcomes. With researchers from diverse fields contributing, there is a unique opportunity to benefit from the various inputs in developing a methodological foundation for timely and robust assessments during future pandemics. This will however require a thorough examination of the present methodologies in order to share lessons learnt and develop best practices. Our systematic review can be viewed as a first such attempt.

5 Materials and methods

603

612

613

615

622

We tailored our review to the challenge of mapping a potentially diverse set methodologies from
a large number of studies. To ensure rigour and consistency, we preregistered the procedures for
all stages of the review process, following common guidelines for systematic literature reviews¹⁷.
Certain guidelines were not applicable to a methodology review as ours. In particular, our eligibility
criteria and risk of bias assessment reflect the objective of this review, which was not to evaluate the
effects of non-pharmaceutical interventions, but to map the variation in methodologies used. The
preregistered methodology was documented in a review protocol at PROSPERO¹⁹.
We report our review according to the PRISMA 2020 statement¹⁸. A completed PRISMA 2020

We report our review according to the PRISMA 2020 statement¹⁸. A completed PRISMA 2020 checklist is provided in SI Appendix G. We conceptualized the review by drawing on experience from our own primary research in the field^{4,97}. The search strategy was developed jointly and executed by an experienced information consultant. Then, two authors (NB and AL) performed study selection, data extraction, and synthesis, while having regular meetings with the complete author team.

5.1 Eligibility criteria for studies

In the following, we describe our eligibility criteria, which informed our search strategy and were systematically applied during study selection. Importantly, if a study contained multiple analyses of which only some fulfilled our eligibility criteria, we included the study but extracted only the eligible analyses. This may sometimes not correspond to the main analysis of a paper or may include more than one analysis per study.

Study design

In this review, we considered observational studies assessing the effects of non-pharmaceutical interventions on outcomes related to the COVID-19 disease. We focused on retrospective analyses that used real-world observational data to assess the effects of non-pharmaceutical interventions. Specifically, we excluded modeling studies that predominantly worked with synthetic data or projected future transmission dynamics based on hypothetical scenarios without assessing the effects of interventions empirically.

Population

629

636

We considered studies assessing the effects of non-pharmaceutical interventions on the population in one or several geographic regions. Our review was not limited to a specific geographic region, i. e. all national and subnational regions worldwide were considered. We furthermore included studies analyzing specific subpopulations in a certain region (e. g. certain age groups). We also considered analyses using individual-level data, as long as the intervention effect was assessed on a population level.

Outcome

The main outcomes considered were health-related outcomes at population level that are associated with COVID-19 (e.g. confirmed cases, hospitalizations, and deaths), and epidemiological outcomes characterizing infection dynamics such as reproduction numbers or transmission rates. We also considered similar outcomes associated with other infectious diseases (e.g. influenza), if used as a surrogate for COVID-19. Moreover, behavioral outcomes potentially mediating the effect of non-pharmaceutical interventions were included (e.g. human mobility). In contrast, we excluded analyses assessing the effects of non-pharmaceutical interventions solely on other outcomes not directly related to infectious diseases (e.g. psychological well-being or economic activities).

Intervention

645

As non-pharmaceutical interventions, we considered the implementation of health policy measures in 646 the context of the COVID-19 pandemic. Specifically, we included any intervention related to social distancing (e.g. school closures, venue closures, workplace closures), containment (e.g. contact 648 tracing, quarantining), population flow (e.g. border closures), or personal protection (e.g. facial 649 mask mandates). Analyses were considered regardless of whether they assessed the effect of a 650 single intervention, the effects of multiple interventions separately, or the effect of a combination 651 of interventions. For simplicity, we refer to these as non-pharmaceutical interventions throughout 652 the review, while recognizing that also other terms have been used in the literature. Importantly, 653 we accounted for various alternative terms in our literature search (see Search strategy below). We excluded interventions not directly related to disease control (e.g. economic measures like social 655 benefits). 656

5.2 Search strategy

661

662

663

664

665

666

667

668

669

Our search strategy was informed by our personal experience with studies in the field from our own primary research on the impact of non-pharmaceutical interventions. The search was supported by an experienced information consultant.

We searched for peer-reviewed original research articles in English language that were accepted, published, or in press between January 1, 2020 and January 12, 2021. In our review protocol, we specified that we would also include preprints in our search. However, due to their enormous volume, we eventually decided not to consider gray literature or preprints in our review. Our results therefore only cover methodologies used by articles peer-reviewed at the time of search, among which we already found considerable variation. To account for potentially new methodologies in articles published after the time of search, we also considered further recent studies on the effects of non-pharmaceutical interventions in our discussion and put them into the context of our review findings.

We searched the databases Embase, PubMed, Scopus, and Web of Science. These databases 670 include, among others, MEDLINE, Biological Abstracts, CAB Abstracts, and Global Health. We 671 composed our search query of four components to be contained in the publication title or abstract: 672 (1) a synonym for "non-pharmaceutical intervention", (2) a synonym for "estimation" or "assessment", 673 (3) a synonym for "effect", and (4) a synonym for "COVID-19". Starting from a precompiled list 674 of 18 references based on our primary research on the effects of non-pharmaceutical interventions, 675 we created and repeatedly extended a collection of synonyms for each of the above components, 676 thereby achieving a broad search while keeping the number of selected studies manageable. The 677 strings for our search queries are provided in SI Appendix B. Importantly, we decided not to include 678 search terms for single interventions such as face masks or travel restrictions, as this would have 679 resulted in an unmanageable number of studies that were not concerned with the population-level 680 impact of the non-pharmaceutical intervention. Nevertheless, our search query found studies on 681 single interventions through other terms describing non-pharmaceutical interventions. 682

5.3 Data collection and analysis

Study selection

As a first step, we screened the titles of the studies retrieved from the database search for keywords 685 clearly suggesting that the study would not meet our predefined eligibility criteria (e.g. "mental health" or "air quality"). The compiled set of keywords (see SI Appendix B) was used to automatically identify cases for exclusion via the publication title. For all remaining studies, two authors (AL and 688 NB) checked the eligibility criteria and individually decided on inclusion or exclusion. Each of the 689 two authors checked the eligibility for one half of the studies via the following process: First, studies 690 were checked by title and, if in doubt, by abstract. Then, if still in doubt, studies were checked by 691 full text and discussed by both authors. Any disagreements were resolved with involvement of a 692 third author (WV). Generally, we followed an inclusive approach by keeping all studies that could 693 not be excluded with high confidence. At each stage, all decisions were recorded in a spreadsheet. 694

Data extraction

We extracted data from all included studies in a spreadsheet. Our extraction strategy reflected the 696 exploratory nature of our analysis and thus allowed for new data items to be added throughout 697 the process. Therefore, we maintained a detailed manual with all data items and the potential values for each item (see SI Appendix D). Before extraction, a preliminary version of the data 699 extraction form was created based on reporting items from checklists for observational studies 700 (STROBE¹⁰⁶, RECORD¹⁰⁷), a template for public health policy interventions (TIDieR-PHP¹⁰⁸), and our personal experience with studies in the field from our own primary research on the impact 702 of non-pharmaceutical interventions. Aside from bibliographic information, the data to be extracted 703 consisted of information on the study setting, outcome, intervention, methodological approach, and 704 effect assessment. 705

The extraction process was structured in four rounds. During the first round, two authors (AL and NB) extracted data from an initial set of 20 publications, blinded to each other's coding. The coding was then compared, and any differences were discussed to resolve ambiguities. Corresponding changes were recorded by updating the extraction form and manual, and applied subsequently. In the second round, the two reviewers each extracted data from one half of the remaining publications and checked the other half coded by their colleague. Color-coding was used to highlight uncertain

or ambiguous entries for the other reviewer or to mark such entries for further discussion. Regular meetings were held between the two authors (AL and NB) to discuss these uncertainties and 713 ambiguities. All disagreements were resolved through discussion, if needed by involving a third 714 author (WV). Thereby, the data extraction manual and form were continuously refined and kept 715 up-to-date. In particular, the list of values that could be potentially assigned to each data item was 716 continuously extended and harmonized as new studies were extracted. In the third round, the data 717 extraction form and manual were simplified by merging data items or categories that, retrospectively, were found redundant, or by relabeling items and categories to define them more precisely. This 719 was done with particular attention to enable comparability among the extracted analyses as well as 720 readability of the results. In the fourth round, the final scheme was applied to all studies.

Quality assessment

722

732

The goal of this systematic review was not to perform a meta-analysis or narrative synthesis of the
effects of non-pharmaceutical interventions, but to compare the included studies along methodological
dimensions and to analyze the variation in study setting, outcome, intervention, methodological
approach, and effect assessment. Therefore, no risk of bias assessment with regard to the study
results was conducted. Our minimum requirement for quality was that most information on the
aforementioned dimensions could be extracted from the manuscript and/or supplementary material.
This minimum requirement was not met by four studies, which were thus excluded. For other studies
where only some methodological information was missing, we noted in the data extraction sheet
that this information "could not be evaluated".

Data synthesis

The results of the data extraction were synthesized in tabular form by recording the frequency of categories per item. We reported the frequency for each item of the main dimensions (study setting, outcome, intervention, methodological approach, and effect assessment) individually. For some items, we conducted further specialized analyses, for example by computing the frequencies of categories for different methodologies separately, or by qualitatively evaluating the supplementary information added to certain entries during extraction. Insights from these additional analyses were reported textually. Furthermore, we synthesized common analysis types based on patterns identified in the methodological approaches. Lastly, based on our findings, we derived specific recommendations for

future studies with regard to scope, robustness, and comparability, and put them into the context of

more recent studies that were not part of our review sample.

References

- 744 1. Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A Global Panel
- Database of Pandemic Policies (Oxford COVID-19 Government Response Tracker). Nature
- 746 Human Behaviour. 2021;5(4):529–538.
- ⁷⁴⁷ 2. Brauner JM, Mindermann S, Sharma M, Johnston D, Salvatier J, Gavenčiak T, et al. Inferring the
- Effectiveness of Government Interventions against COVID-19. Science. 2021;371(6531):eabd9338.
- 3. Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, et al. Ranking the
- 750 Effectiveness of Worldwide COVID-19 Government Interventions. Nature Human Behaviour.
- 751 2020;4(12):1303–1312.
- ⁷⁵² 4. Banholzer N, van Weenen E, Lison A, Cenedese A, Seeliger A, Kratzwald B, et al. Estimating the
- ⁷⁵³ Effects of Non-Pharmaceutical Interventions on the Number of New Infections with COVID-19
- during the First Epidemic Wave. PLOS ONE. 2021;16(6):e0252827.
- ⁷⁵⁵ **5.** Auger KA, Shah SS, Richardson T, Hartley D, Hall M, Warniment A, et al. Association
- between Statewide School Closure and COVID-19 Incidence and Mortality in the US. JAMA.
- 2020;324(9):859–870.
- 758 6. Bennett M. All Things Equal? Heterogeneity in Policy Effectiveness against COVID-19 Spread
- in Chile. World Development. 2021;137:105208.
- 7. Courtemanche C, Garuccio J, Le A, Pinkston J, Yelowitz A. Strong Social Distancing Measures
- in the United States Reduced the COVID-19 Growth Rate. Health Affairs. 2020;39(7):1237–1246.
- 8. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the Effects
- of Non-Pharmaceutical Interventions on COVID-19 in Europe. Nature. 2020;584(7820):257–261.
- 9. Hsiang S, Allen D, Annan-Phan S, Bell K, Bolliger I, Chong T, et al. The Effect of Large-Scale
- Anti-Contagion Policies on the COVID-19 Pandemic. Nature. 2020;584(7820):262–267.
- 10. Lemaitre JC, Perez-Saez J, Azman AS, Rinaldo A, Fellay J. Assessing the Impact of Non-
- Pharmaceutical Interventions on SARS-CoV-2 Transmission in Switzerland. Swiss Medical Weekly.
- 768 2020;150:w20295.

- 11. Mendez-Brito A, Bcheraoui CE, Pozo-Martin F. Systematic Review of Empirical Studies
- Comparing the Effectiveness of Non-Pharmaceutical Interventions against COVID-19. Journal of
- Infection. 2021;83(3):281–293.
- 12. Poeschl J, Larsen RB. How Do Non- Pharmaceutical Interventions Affect the Spread of
- COVID-19? A Literature Review. Danmarks Nationalbank; 2021. 4.
- 13. Rizvi RF, Craig KJT, Hekmat R, Reyes F, South B, Rosario B, et al. Effectiveness of Non-
- Pharmaceutical Interventions Related to Social Distancing on Respiratory Viral Infectious Disease
- Outcomes: A Rapid Evidence-Based Review and Meta-Analysis. SAGE Open Medicine. 2021;9.
- 14. Iezadi S, Gholipour K, Azami-Aghdash S, Ghiasi A, Rezapour A, Pourasghari H, et al. Effec-
- tiveness of Non-Pharmaceutical Public Health Interventions against COVID-19: A Systematic
- Review and Meta-Analysis. PLOS ONE. 2021;16(11):e0260371.
- 780 15. Talic S, Shah S, Wild H, Gasevic D, Maharaj A, Ademi Z, et al. Effectiveness of Public Health
- Measures in Reducing the Incidence of COVID-19, SARS-CoV-2 Transmission, and Covid-19
- Mortality: Systematic Review and Meta-Analysis. BMJ. 2021;375:e068302.
- 16. Perra N. Non-Pharmaceutical Interventions during the COVID-19 Pandemic: A Review. Physics
- Reports. 2021;913:1–52.
- ⁷⁸⁵ 17. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for
- 786 Systematic Reviews of Interventions. Cochrane; 2021.
- 18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA
- ⁷⁸⁸ 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ. 2021;372:n71.
- 19. Banholzer N, Lison A, Özcelik D, Feuerriegel S, Vach W. A Comparison of Studies Estimating the
- 790 Effectiveness of Non-Pharmaceutical Interventions: A Systematic Review Protocol. PROSPERO;
- 791 2021.
- 20. Candido DS, Claro IM, de Jesus JG, Souza WM, Moreira FRR, Dellicour S, et al. Evolution
- and Epidemic Spread of SARS-CoV-2 in Brazil. Science. 2020;369(6508):1255–1260.
- 794 21. Moreno GK, Braun KM, Riemersma KK, Martin MA, Halfmann PJ, Crooks CM, et al. Re-
- vealing Fine-Scale Spatiotemporal Differences in SARS-CoV-2 Introduction and Spread. Nature
- 796 Communications. 2020;11(1):5558.

- ⁷⁹⁷ **22.** Wieland T. A Phenomenological Approach to Assessing the Effectiveness of COVID-19 Related
- Nonpharmaceutical Interventions in Germany. Safety Science. 2020;131:104924.
- 23. Karnakov P, Arampatzis G, Kii I, Wermelinger F, Wlchli D, Papadimitriou C, et al. Data-
- Driven Inference of the Reproduction Number for COVID-19 before and after Interventions for
- 51 European Countries. Swiss Medical Weekly. 2020;150:w20313.
- 24. Cori A, Ferguson NM, Fraser C, Cauchemez S. A New Framework and Software to Estimate
- Time-Varying Reproduction Numbers During Epidemics. American Journal of Epidemiology.
- 2013;178(9):1505–1512.
- 25. Cori A. EpiEstim: Estimate Time Varying Reproduction Numbers from Epidemic Curves; 2021.
- 26. Diekmann O, Heesterbeek JAP, Metz JAJ. On the Definition and the Computation of the Basic
- Reproduction Ratio R0 in Models for Infectious Diseases in Heterogeneous Populations. Journal
- of Mathematical Biology. 1990;28(4):365–382.
- 27. Wallinga J, Teunis P. Different Epidemic Curves for Severe Acute Respiratory Syndrome Reveal
- Similar Impacts of Control Measures. American Journal of Epidemiology. 2004;160(6):509–516.
- 28. Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the Effect of Individual
- Variation on Disease Emergence. Nature. 2005;438(7066):355–359.
- 813 **29.** European Centre for Disease Prevention and Control. COVID-19 Datasets; 2022.
- https://www.ecdc.europa.eu/en/covid-19/data.
- 30. Johns Hopkins University & Medicine. Coronavirus Resource Center; 2022.
- https://coronavirus.jhu.edu/.
- 31. Worldometer. Coronavirus Statistics; 2022. https://www.worldometers.info/coronavirus/.
- 818 **32.** Google. COVID-19 Community Mobility Reports; 2022.
- https://www.google.com/covid19/mobility/.
- 33. Apple. COVID-19 Mobility Trends Reports; 2022. https://covid19.apple.com/mobility.
- 34. China Data Lab. Baidu Mobility Data; 2021. https://doi.org/10.7910/DVN/FAEZIO.
- 35. Kucharski AJ, Russell TW, Diamond C, Liu Y, Edmunds J, Funk S, et al. Early Dynamics of
- Transmission and Control of COVID-19: A Mathematical Modelling Study. The Lancet Infectious
- Diseases. 2020;20(5):553–558.

- 36. Couzin-Frankel J, Vogel G. School Openings across Globe Suggest Ways to Keep Coronavirus at Bay, despite Outbreaks. Science: 2021.
- 37. Berry CR, Fowler A, Glazer T, Handel-Meyer S, MacMillen A. Evaluating the Effects of Shelter-in-Place Policies during the COVID-19 Pandemic. Proceedings of the National Academy of Sciences. 2021;118(15):e2019706118.
- 38. Bönisch S, Wegscheider K, Krause L, Sehner S, Wiegel S, Zapf A, et al. Effects of Coronavirus

 Disease (COVID-19) Related Contact Restrictions in Germany, March to May 2020, on the

 Mobility and Relation to Infection Patterns. Frontiers in Public Health. 2020;8:568287.
- 39. Kraemer MUG, Yang CH, Gutierrez B, Wu CH, Klein B, Pigott DM, et al. The Effect of Human

 Mobility and Control Measures on the COVID-19 Epidemic in China. Science. 2020;368(6490):493–

 497.
- 40. Salvatore M, Basu D, Ray D, Kleinsasser M, Purkayastha S, Bhattacharyya R, et al. Comprehensive Public Health Evaluation of Lockdown as a Non-Pharmaceutical Intervention on
 COVID-19 Spread in India: National Trends Masking State-Level Variations. BMJ Open.
 2020;10(12):e041778.
- 41. Ali ST, Wang L, Lau EHY, Xu XK, Du Z, Wu Y, et al. Serial Interval of SARS-CoV-2 Was
 Shortened over Time by Nonpharmaceutical Interventions. Science. 2020;369(6507):1106–1109.
- 42. Price DJ, Shearer FM, Meehan MT, McBryde E, Moss R, Golding N, et al. Early Analysis of
 the Australian COVID-19 Epidemic. eLife. 2020;9:e58785.
- 43. Huber M, Langen H. Timing Matters: The Impact of Response Measures on COVID-19-related
 Hospitalization and Death Rates in Germany and Switzerland. Swiss Journal of Economics and
 Statistics. 2020;156(1):1–19.
- 44. Pullano G, Valdano E, Scarpa N, Rubrichi S, Colizza V. Evaluating the Effect of Demographic
 Factors, Socioeconomic Factors, and Risk Aversion on Mobility during the COVID-19 Epidemic in
 France under Lockdown: A Population-Based Study. The Lancet Digital Health. 2020;2(12):e638–e649.
- 45. Jefferies S, French N, Gilkison C, Graham G, Hope V, Marshall J, et al. COVID-19 in New Zealand and the Impact of the National Response: A Descriptive Epidemiological Study. The

Lancet Public Health. 2020;5(11):e612–e623. 853

865

- 46. Maier BF, Brockmann D. Effective Containment Explains Subexponential Growth in Recent 854 Confirmed COVID-19 Cases in China. Science. 2020;368(6492):742-746. 855
- 47. Collins OC, Duffy KJ. Estimating the Impact of Lock-down, Quarantine and Sensitization in a 856 COVID-19 Outbreak: Lessons from the COVID-19 Outbreak in China. Peer J. 2020;8:e9933. 857
- 48. Braithwaite J, Tran Y, Ellis LA, Westbrook J. The 40 Health Systems, COVID-19 (40HS, C-19) 858 Study. International Journal for Quality in Health Care. 2020;33(1):mzaa113. 859
- 49. Koh WC, Naing L, Wong J. Estimating the Impact of Physical Distancing Measures in 860 Containing COVID-19: An Empirical Analysis. International Journal of Infectious Diseases. 861 2020;100:42-49. 862
- 50. Gupta M, Mohanta SS, Rao A, Parameswaran GG, Agarwal M, Arora M, et al. Transmission 863 Dynamics of the COVID-19 Epidemic in India and Modeling Optimal Lockdown Exit Strategies. 864 International Journal of Infectious Diseases. 2021;103:579–589.
- 51. New York Times. See Reopening Plans and Mask Manadates for All 50 States; 2021. 866 https://www.nytimes.com/interactive/2020/us/states-reopen-map-coronavirus.html. 867
- 52. McGrail DJ, Dai J, McAndrews KM, Kalluri R. Enacting National Social Distancing 868 Policies Corresponds with Dramatic Reduction in COVID19 Infection Rates. PLOS ONE. 2020;15(7):e0236619.870
- 53. Scarabel F, Pellis L, Bragazzi NL, Wu J. Canada Needs to Rapidly Escalate Public Health 871 Interventions for Its COVID-19 Mitigation Strategies. Infectious Disease Modelling. 2020;5:316— 872 322. 873
- **54.** Guirao A. The COVID-19 Outbreak in Spain. A Simple Dynamics Model, Some Lessons, and a Theoretical Framework for Control Response. Infectious Disease Modelling. 2020;5:652–669. 875
- 55. Krishna MV. Mathematical Modelling on Diffusion and Control of COVID-19. Infectious 876 Disease Modelling. 2020;5:588–597. 877
- 56. Zhang B, Zhou H, Zhou F. Study on SARS-CoV-2 Transmission and the Effects of Control 878 Measures in China. PLOS ONE. 2020;15(11):e0242649. 879

- 57. Sebastiani G, Massa M, Riboli E. COVID-19 Epidemic in Italy: Evolution, Projections and
 Impact of Government Measures. European Journal of Epidemiology. 2020:35(4):341–345.
- 58. Valencia M, Becerra JE, Reyes JC, Castro KG. Assessment of Early Mitigation Measures
 against COVID-19 in Puerto Rico: March 15-May 15, 2020. PLOS ONE. 2020;15(10):e0240013.
- 59. Riccardo F, Ajelli M, Andrianou XD, Bella A, Manso MD, Fabiani M, et al. Epidemiological

 Characteristics of COVID-19 Cases and Estimates of the Reproductive Numbers 1 Month into

 the Epidemic, Italy, 28 January to 31 March 2020. Eurosurveillance. 2020;25(49):2000790.
- 60. Gao S, Rao J, Kang Y, Liang Y, Kruse J, Dopfer D, et al. Association of Mobile Phone Location
 Data Indications of Travel and Stay-at-Home Mandates with COVID-19 Infection Rates in the
 US. JAMA Network Open. 2020;3(9):e2020485.
- 61. Lurie MN, Silva J, Yorlets RR, Tao J, Chan PA. Coronavirus Disease 2019 Epidemic Doubling
 Time in the United States before and during Stay-at-Home Restrictions. The Journal of Infectious
 Diseases. 2020;222(10):1601–1606.
- 62. Jarvis CI, Zandvoort aKV, Gimma A, Prem K, Klepac P, Rubin GJ, et al. Quantifying the
 Impact of Physical Distance Measures on the Transmission of COVID-19 in the UK. BMC
 Medicine. 2020;18(1).
- 63. Ng Y, Li Z, Chua YX, Chaw WL, Zhao Z, Er B, et al. Evaluation of the Effectiveness of
 Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore
 January 2–February 29, 2020. Morbidity and Mortality Weekly Report. 2020;69(11):307–311.
- 64. Cobb JS, Seale MA. Examining the Effect of Social Distancing on the Compound Growth Rate of COVID-19 at the County Level (United States) Using Statistical Analyses and a Random Forest Machine Learning Model. Public Health. 2020;185:27–29.
- 65. Jardine R, Wright J, Samad Z, Bhutta ZA. Analysis of COVID-19 Burden, Epidemiology and
 Mitigation Strategies in Muslim Majority Countries. Eastern Mediterranean Health Journal.
 2020;26(10):1173-1183.
- 66. Murillo-Zamora E, Guzmán-Esquivel J, Sánchez-Piña RA, Cedeño-Laurent G, Delgado-Enciso
 I, Mendoza-Cano O. Physical Distancing Reduced the Incidence of Influenza and Supports a

- Favorable Impact on SARS-CoV-2 Spread in Mexico. The Journal of Infection in Developing
- 908 Countries. 2020;14(9):953–956.
- 67. Verma BK, Verma M, Verma VK, Abdullah RB, Nath DC, Khan HTA, et al. Global Lockdown:
- An Effective Safeguard in Responding to the Threat of COVID-19. Journal of Evaluation in
- 911 Clinical Practice. 2020;26(6):1592–1598.
- 68. Islam N, Sharp SJ, Chowell G, Shabnam S, Kawachi I, Lacey B, et al. Physical Distancing
- Interventions and Incidence of Coronavirus Disease 2019: Natural Experiment in 149 Countries.
- 914 BMJ. 2020;370:m2743.
- 69. Wagner AB, Hill EL, Ryan SE, Sun Z, Deng G, Bhadane S, et al. Social Distancing Merely
- Stabilized COVID-19 in the United States. Stat. 2020;9(1):e302.
- 70. Silva L, Filho DF, Fernandes A. The Effect of Lockdown on the COVID-19 Epidemic
- in Brazil: Evidence from an Interrupted Time Series Design. Cadernos de Saúde Pública.
- 2020;36(10):e00213920.
- 71. Medline A, Hayes L, Valdez K, Hayashi A, Vahedi F, Capell W, et al. Evaluating the Impact of
- Stay-at-Home Orders on the Time to Reach the Peak Burden of COVID-19 Cases and Deaths:
- Does Timing Matter? BMC Public Health. 2020;20:1750.
- 72. Arshed N, Meo MS, Farooq F. Empirical Assessment of Government Policies and Flattening of
- the COVID 19 Curve. Journal of Public Affairs. 2020;20:e2333.
- 73. Holtz D, Zhao M, Benzell SG, Cao CY, Rahimian MA, Yang J, et al. Interdependence and
- the Cost of Uncoordinated Responses to COVID-19. Proceedings of the National Academy of
- 927 Sciences. 2020;117(33):19837–19843.
- 928 74. Li Y, Campbell H, Kulkarni D, Harpur A, Nundy M, Wang X, et al. The Temporal Association of
- 929 Introducing and Lifting Non-Pharmaceutical Interventions with the Time-Varying Reproduction
- Number (R) of SARS-CoV-2: A Modelling Study across 131 Countries. The Lancet Infectious
- Diseases. 2021;21(2):193–202.
- 75. Salje H, Kiem CT, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the Burden
- of SARS-CoV-2 in France. Science. 2020;369(6500):208-211.

- 76. Gatto M, Bertuzzo E, Mari L, Miccoli S, Carraro L, Casagrandi R, et al. Spread and Dynamics
- of the COVID-19 Epidemic in Italy: Effects of Emergency Containment Measures. Proceedings
- of the National Academy of Sciences. 2020;117(19):10484–10491.
- 77. Dehning J, Zierenberg J, Spitzner FP, Wibral M, Neto JP, Wilczek M, et al. Inferring
- Change Points in the Spread of COVID-19 Reveals the Effectiveness of Interventions. Sci-
- ence. 2020;369(6500):eabb9789.
- ⁹⁴⁰ **78.** Anderson SC, Edwards AM, Yerlanov M, Mulberry N, Stockdale JE, Iyaniwura SA, et al.
- Quantifying the Impact of COVID-19 Control Measures Using a Bayesian Model of Physical
- Distancing. PLOS Computational Biology. 2020;16(12):e1008274.
- 943 79. Wang T, Wu Y, Lau JYN, Yu Y, Liu L, Li J, et al. A Four-Compartment Model for the
- 944 COVID-19 Infection Implications on Infection Kinetics, Control Measures, and Lockdown Exit
- 945 Strategies. Precision Clinical Medicine. 2020;3(2):104–112.
- 946 80. McCarthy Z, Xiao Y, Scarabel F, Tang B, Bragazzi NL, Nah K, et al. Quantifying the
- Shift in Social Contact Patterns in Response to Non-Pharmaceutical Interventions. Journal of
- 948 Mathematics in Industry. 2020;10:28.
- 949 81. Dandekar R, Rackauckas C, Barbastathis G. A Machine Learning-Aided Global Diagnostic
- and Comparative Tool to Assess Effect of Quarantine Control in COVID-19 Spread. Patterns.
- 951 2020;1(9):100145.
- 82. Crokidakis N. COVID-19 Spreading in Rio de Janeiro, Brazil: Do the Policies of Social Isolation
- Really Work? Chaos, Solitons & Fractals. 2020;136:109930.
- 954 83. Ge J, He D, Lin Z, Zhu H, Zhuang Z. Four-Tier Response System and Spatial Propagation of
- 955 COVID-19 in China by a Network Model. Mathematical Biosciences. 2020;330:108484.
- 956 84. Manevski D, Gorenjec NR, Kejžar N, Blagus R. Modeling COVID-19 Pandemic Using Bayesian
- Analysis with Application to Slovene Data. Mathematical Biosciences. 2020;329:108466.
- 958 85. Li BZ, Cao NW, Zhou HY, Chu XJ, Ye DQ. Strong Policies Control the Spread of COVID-19
- 959 in China. Journal of Medical Virology. 2020;92(10):1980–1987.
- 960 86. Zhao S, Chen H. Modeling the Epidemic Dynamics and Control of COVID-19 Outbreak in
- 961 China. Quantitative Biology. 2020;8(1):11–19.

- 87. Shi Q, Hu Y, Peng B, Tang XJ, Wang W, Su K, et al. Effective Control of SARS-CoV-2
 Transmission in Wanzhou, China. Nature Medicine. 2020;27(1):86–93.
- 88. Adekunle A, Meehan M, Rojas-Alvarez D, Trauer J, McBryde E. Delaying the COVID-19
- Epidemic in Australia: Evaluating the Effectiveness of International Travel Bans. Australian and
- New Zealand Journal of Public Health. 2020;44(4):257–259.
- 89. Li Y, Wang LW, Peng ZH, Shen HB. Basic Reproduction Number and Predicted Trends of
- Coronavirus Disease 2019 Epidemic in the Mainland of China. Infectious Diseases of Poverty.
- 969 2020;9:94.
- 970 90. Kendall M, Milsom L, Abeler-Dörner L, Wymant C, Ferretti L, Briers M, et al. Epidemiological
- 971 Changes on the Isle of Wight after the Launch of the NHS Test and Trace Programme: A
- 972 Preliminary Analysis. The Lancet Digital Health. 2020;2(12):e658–e666.
- 973 91. Kang N, Kim B. The Effects of Border Shutdowns on the Spread of COVID-19. Journal of
- Preventive Medicine and Public Health. 2020;53(5):293–301.
- 975 92. Tian T, Luo W, Tan J, Jiang Y, Chen M, Pan W, et al. The Timing and Effectiveness of
- Implementing Mild Interventions of COVID-19 in Large Industrial Regions via a Synthetic
- 977 Control Method. Statistics and Its Interface. 2021;14(1):3–12.
- 93. Marschner IC. Back-Projection of COVID-19 Diagnosis Counts to Assess Infection Incidence
- and Control Measures: Analysis of Australian Data. Epidemiology and Infection. 2020;148:e97.
- 980 94. Valcarcel B, Avilez JL, Torres-Roman JS, Poterico JA, Bazalar-Palacios J, Vecchia CL. The
- effect of Early-Stage Public Health Policies in the Transmission of COVID-19 for South American
- Countries. Revista Panamericana de Salud Pública. 2020;44:e148.
- 983 95. Wong CKH, Wong JYH, Tang EHM, Au CH, Lau KTK, Wai AKC. Impact of National
- 984 Containment Measures on Decelerating the Increase in Daily New Cases of COVID-19 in 54
- countries and 4 Epicenters of the Pandemic: Comparative Observational Study. Journal of
- 986 Medical Internet Research. 2020;22(7):e19904.
- 987 96. Nouvellet P, Bhatia S, Cori A, Ainslie KEC, Baguelin M, Bhatt S, et al. Reduction in Mobility
- and COVID-19 Transmission. Nature Communications. 2021;12:1090.

- 989 97. Lison A, Persson J, Banholzer N, Feuerriegel S. Estimating the Effect of Mobility on SARS-
- cov-2 Transmission during the First and Second Wave of the COVID-19 Epidemic, Switzerland,
- 991 March to December 2020. Eurosurveillance. 2022;27(10):2100374.
- 992 98. Coletti P, Wambua J, Gimma A, Willem L, Vercruysse S, Vanhoutte B, et al. CoMix: Comparing
- Mixing Patterns in the Belgian Population during and after Lockdown. Scientific Reports.
- 994 2020;10:21885.
- 995 99. Chernozhukov V, Kasahara H, Schrimpf P. Causal impact of masks, policies, behavior on early
- covid-19 pandemic in the U.S. Journal of Econometrics. 2021;220(1):23–62.
- 997 100. Persson J, Parie JF, Feuerriegel S. Monitoring the COVID-19 Epidemic with Na-
- tionwide Telecommunication Data. Proceedings of the National Academy of Sciences.
- 999 2021;118(26):e2100664118.
- 100. Shen Y, Powell G, Ganser I, Zheng Q, Grundy C, Okhmatovskaia A, et al. Monitoring
- Non-Pharmaceutical Public Health Interventions during the COVID-19 Pandemic. Scientific
- Data. 2021;8:225.
- 1003 102. Allcott H, Boxell L, Conway JC, Ferguson BA, Gentzkow M, Goldman B. What Explains
- 1004 Temporal and Geographic Variation in the Early US Coronavirus Pandemic? National Bureau of
- 1005 Economic Research; 2020. 27965.
- 1006 103. Yan Y, Malik AA, Bayham J, Fenichel EP, Couzens C, Omer SB. Measuring Voluntary and
- Policy-Induced Social Distancing Behavior during the COVID-19 Pandemic. Proceedings of the
- National Academy of Sciences. 2021;118(16):e2008814118.
- 1009 104. Grossman G, Kim S, Rexer JM, Thirumurthy H. Political partisanship influences behav-
- ioral responses to governors' recommendations for COVID-19 prevention in the United States.
- Proceedings of the National Academy of Sciences. 2020;117(39):24144–24153.
- 105. Herby J. A First Literature Review: Lockdowns Only Had a Small Effect on COVID-19. Social
- Science Research Network; 2021. 3764553.
- 106. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al.
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation
- and elaboration. Epidemiology (Cambridge, Mass). 2007;18(6):805–835.

- 1017 107. Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting
- of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.
- PLoS Medicine. 2015;12(10):e1001885.
- 1020 108. Campbell M, Katikireddi SV, Hoffmann T, Armstrong R, Waters E, Craig P. TIDieR-PHP: a
- reporting guideline for population health and policy interventions. BMJ. 2018;361:k1079.

Declarations

1022

1023

1025

1033

Ethics approval

1024 Ethics approval was not required for this study.

Competing interests

SF reports membership in a COVID-19 working group of the World Health Organization but without competing interest. SF reports grants from the Swiss National Science Foundation outside of the

submitted work. All authors declare no competing interests.

1029 Funding

 1030 NB and SF acknowledge funding from the Swiss National Science Foundation (SNSF) as part of the

Eccellenza grant 186932 on "Data-driven health management". The funding bodies had no control

over design, conduct, data, analysis, review, reporting, or interpretation of the research conducted.

Contributions

NB and AL contributed to conceptualization, literature search, study selection, data extraction,

data synthesis, and manuscript writing, review & editing. DO contributed to literature search and

manuscript review & and editing. TS contributed to manuscript review & editing. SF contributed

to manuscript writing, review & editing. WV contributed to conceptualization, study selection, data

1038 extraction, data synthesis, manuscript writing, review & editing.

1039 Data availability

1040 The full data extracted from the studies in this review is available in machine-readable format at

1041 https://github.com/adrian-lison/methodologies-npi-effects.